ADVERTISEMENT
Novel Biofilm Disruption Technology Platform Available
Dermalink Technologies Inc (Pennington, NJ) announced the development of its new biofilm-disrupting products for the US wound care market. The core product ingredient, lauroyl arginine ethylester (LAE), has been used as an anti-biofilm in European food and dental markets. This ingredient has been demonstrated to reduce microbial adherence to tissue and dressing materials as well as disrupt intact biofilms and anti-quorum forming activity.
The first of the company’s portfolio of products includes a LAE hydrogel and wound cleanser/infusion solution. The company is seeking commercial partners to champion additional support studies and marketing/distribution channels in the United States and Europe.
Click here for more information.
Advertisement
Reimbursement Library From A to Z
Subscribe and never miss an article!
Advertisement
Coping With COVID-19
Advertisement